New york, july 19, 2017 /prnewswire/ — neurotrope, inc. Ntrp) today presented clinical results from its recently completed phase 2 trial demonstrating that moderate-to-severe alzheimer's. New york, feb.

Snpx) announced today that it has received its first batch of synthetic bryostatin. The company has an exclusive licensing. Apoe4 and a oligomers reduce bdnf expression via hdac nuclear translocation abhik sen, thomas j. Nelson, and daniel l. Synaptogenix | portfolio categories map 262 april 6, 2018in princeton map

Synaptogenix | portfolio categories map 262 april 6, 2018in princeton map